Company intelligence / Profile preview
eTheRNA immunotherapies
Niel, Antwerp, Belgiumetherna.be ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Preclinical
01
Overview
eTheRNA has demonstrated safety and early efficacy signals in clinical studies of its TriMix-based mRNA cancer vaccines. Its metastatic melanoma vaccine has reached Phase Ib/IIa trials in Europe. Preclinical data support the expansion into infectious disease vaccines.
- Therapeutic areas
- OncologyCardiovascularInfectious Diseases
- Modalities
- mRNA therapeuticsmRNA vaccinesLipid Nanoparticle (LNP) delivery systemsImmunostimulants/Immunotherapy agentsDendritic cell vaccines
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
Merck KGaADropshot TherapeuticsGrand Pharmaceutical Group/HK
Beyond the preview
Go deeper on eTheRNA immunotherapies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eTheRNA immunotherapies.